ABSTRACT
Some endocrine disorders, including hypophysitis and isolated adrenocorticotropic hormone (ACTH) deficiency, are caused by an autoimmune response to endocrine organs. Although the pathogenesis of some autoimmune endocrine diseases has been elucidated, it remains obscure for most. Anti-PIT-1 hypophysitis (anti-PIT-1 antibody syndrome) is a newly described pituitary autoimmune disease characterized by acquired and specific growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) deficiencies. This disorder is associated with a thymoma or neoplasm that ectopically expresses pituitary-specific transcription factor 1 (PIT-1) protein. Circulating anti-PIT-1 antibody is a disease marker, and PIT-1-reactive cytotoxic T cells (CTLs) play a pivotal role in disease development. In addition, isolated ACTH deficiency appears to be caused by autoimmunity to corticotrophs; however, the pathogenesis remains unclear. A recently described case of isolated ACTH deficiency with large cell neuroendocrine carcinoma (LCNEC) showed ectopically expressed proopiomelanocortin (POMC), and circulating anti-POMC antibody and POMC-reactive CTLs were also detected. As CTL infiltrations around corticotrophs were also observed, isolated ACTH deficiency may be associated at least in part with a paraneoplastic syndrome. Although several underlying mechanisms for pituitary autoimmunity have been proposed, these observations highlight the importance of paraneoplastic syndrome as a cause of pituitary autoimmune disease. In this review, we focus on the pathophysiology and connection of anti-PIT-1 hypophysitis and isolated ACTH deficiency and discuss the state-of-art knowledge for understanding pituitary autoimmunity.
Subject(s)
Adrenocorticotropic Hormone/deficiency , Autoimmune Diseases of the Nervous System , Autoimmune Hypophysitis , Endocrine System Diseases , Genetic Diseases, Inborn , Hypoglycemia , Paraneoplastic Syndromes , Pituitary Diseases , Adrenocorticotropic Hormone/immunology , Adrenocorticotropic Hormone/metabolism , Autoimmune Diseases of the Nervous System/immunology , Autoimmune Diseases of the Nervous System/metabolism , Autoimmune Hypophysitis/immunology , Autoimmune Hypophysitis/metabolism , Endocrine System Diseases/immunology , Endocrine System Diseases/metabolism , Genetic Diseases, Inborn/immunology , Genetic Diseases, Inborn/metabolism , Humans , Hypoglycemia/immunology , Hypoglycemia/metabolism , Paraneoplastic Syndromes/immunology , Paraneoplastic Syndromes/metabolism , Pituitary Diseases/immunology , Pituitary Diseases/metabolismABSTRACT
CONTEXT: Anti-pituitary-specific transcriptional factor-1 (anti-PIT-1) antibody syndrome is characterized by acquired and specific deficiencies in growth hormone, prolactin, and thyroid-stimulating hormone. Although PIT-1-reactive cytotoxic T lymphocytes (CTLs) have been speculated to recognize anterior pituitary cells and to cause the injury in the pathogenesis of the syndrome, it remains unclear whether endogenous PIT-1 protein is processed through the proteolytic pathway and presented as an antigen on anterior pituitary cells. OBJECTIVE: To examine how PIT-1 protein is processed and whether its epitope is presented by major histocompatibility complex (MHC)/HLA class I on anterior pituitary cells. MATERIALS AND METHODS: Immunofluorescence staining and proximity ligation assay (PLA) were performed using anti-PIT-1 antibody and patients' sera on PIT-1-expressing cell line GH3 cells and human induced pluripotent stem cell (iPSC)-derived pituitary tissues. RESULTS: PIT-1 was colocalized with MHC class I molecules, calnexin, and GM130 in the cytosol. PLA results showed that PIT-1 epitope was presented by MHC/HLA class I molecules on the cell surface of GH3 cells and iPSC-derived pituitary cells. The number of PIT-1/HLA complexes on the cell surface of pituitary cells in the patient was comparable with that in the control subject. CONCLUSIONS: Our data indicate that PIT-1 protein is processed in the antigen presentation pathway and that its epitopes are presented by in MHC/HLA class I on anterior pituitary cells, supporting the hypothesis that PIT-1-reactive CTLs caused the cell-specific damage. It is also suggested that number of epitope presentation was not associated with the pathogenesis of anti-PIT-1 antibody syndrome.
ABSTRACT
Various hypothalamic-pituitary diseases cause hypopituitarism. Inflammation related to autoimmunity also causes hypopituitarism. Hypophysitis is a representative disease caused by autoimmunity. Generally, anterior pituitary hormones are non-specifically impaired in this condition, but specific hormone defects have been reported in some cases. Anti-PIT-1 (pituitary-specific transcription factor 1) antibody syndrome is a novel clinical entity that presents an acquired combined pituitary hormone deficiency characterized by a specific defect in growth hormone, prolactin, and thyroid-stimulating hormone. Circulating anti-PIT-1 antibody along with various autoantibodies are detected with multiple endocrine organopathy, meeting the definition of autoimmune polyglandular syndrome. Mechanistically, cytotoxic T lymphocytes that specifically react with PIT-1 protein play an important role in the development of this syndrome.
Subject(s)
Autoantibodies/immunology , Hypopituitarism/immunology , Transcription Factor Pit-1/immunology , Humans , Hypopituitarism/complications , Hypopituitarism/genetics , Polyendocrinopathies, Autoimmune/genetics , Polyendocrinopathies, Autoimmune/immunology , Syndrome , Transcription Factor Pit-1/physiologyABSTRACT
CONTEXT: Anti-pituitary-specific transcriptional factor 1 (PIT-1) antibody syndrome is characterized by acquired growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) deficiencies associated with circulating anti-PIT-1 antibodies. Although autoimmunity to PIT-1 has been suggested as a pathogenesis, the precise mechanism of the syndrome remains unclarified. OBJECTIVE: To elucidate the involvement of antibody- or cell-mediated immunity in anti-PIT-1 antibody syndrome. MATERIALS AND METHODS: To investigate a direct effect of anti-PIT-1 antibody on pituitary cells, cell proliferation, and cytotoxicity detection assays were performed using patient serum. Enzyme-linked immunospot (ELISpot) assay was performed to evaluate the involvement of PIT-1-reactive cytotoxic T lymphocytes (CTLs). An immunohistochemical analysis using anti-CD4 or anti-CD8 antibody was performed to examine tissue infiltration by CTLs. RESULTS: Patient serum did not exhibit any inhibitory effect on cell proliferation and secretion of GH and PRL in GH3 cells. In addition, complement-dependent cytotoxicity was not detected in patient serum on GH3 cells or primary pituitary cells. The ELISpot assay revealed the presence of CTLs that specifically reacted to the recombinant PIT-1 protein in the patient's peripheral lymphocytes. CD8(+) cell infiltrations, which is the characteristic of CTLs, were observed in the pituitary gland, adrenal gland, stomach, thyroid gland, liver, and pancreas of the patient with anti-PIT-1 antibody syndrome. CONCLUSIONS: These results suggest that the anti-PIT-1 antibody is not a cause but a marker of anti-PIT-1 antibody syndrome, in which CTLs play a pivotal role in the pathogenesis.
Subject(s)
Autoantibodies/immunology , Hypothyroidism/immunology , Immunity, Cellular/immunology , Polyendocrinopathies, Autoimmune/immunology , T-Lymphocytes, Cytotoxic/immunology , Transcription Factor Pit-1/immunology , Adult , Aged , Autoantibodies/blood , Biomarkers/blood , Cell Proliferation , Cells, Cultured , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/metabolism , Human Growth Hormone/deficiency , Humans , Hypothyroidism/metabolism , Male , Pituitary Gland/cytology , Pituitary Gland/immunology , Pituitary Gland/metabolism , Polyendocrinopathies, Autoimmune/metabolism , Prolactin/deficiency , T-Lymphocytes, Cytotoxic/metabolism , Thyrotropin/deficiencyABSTRACT
The pituitary-specific transcriptional factor-1 (PIT-1, also known as POU1F1), is an essential factor for multiple hormone-secreting cell types. A genetic defect in the PIT-1 gene results in congenital growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) deficiency. Here, we investigated 3 cases of adult-onset combined GH, PRL, and TSH deficiencies and found that the endocrinological phenotype in each was linked to autoimmunity directed against the PIT-1 protein. We detected anti-PIT-1 antibody along with various autoantibodies in the patients' sera. An ELISA-based screening revealed that this antibody was highly specific to the disease and absent in control subjects. Immunohistochemical analysis revealed that PIT-1-, GH-, PRL-, and TSH-positive cells were absent in the pituitary of patient 2, who also had a range of autoimmune endocrinopathies. These clinical manifestations were compatible with the definition of autoimmune polyendocrine syndrome (APS). However, the main manifestations of APS-I--hypoparathyroidism and Candida infection--were not observed and the pituitary abnormalities were obviously different from the hypophysitis associated with APS. These data suggest that these patients define a unique "anti-PIT-1 antibody syndrome," related to APS.
Subject(s)
Autoantibodies/blood , Human Growth Hormone/deficiency , Polyendocrinopathies, Autoimmune/immunology , Prolactin/deficiency , Thyrotropin/deficiency , Transcription Factor Pit-1/antagonists & inhibitors , Transcription Factor Pit-1/immunology , Adult , Aged , Antibody Specificity , Humans , Immunohistochemistry , Male , Pituitary Gland/metabolism , Polyendocrinopathies, Autoimmune/blood , Polyendocrinopathies, Autoimmune/metabolism , Transcription Factor Pit-1/deficiencyABSTRACT
OBJECTIVE: IGF-I is known to enhance insulin sensitivity in whole body mainly via the IGF-I receptors in muscles. However, the effect of IGF-I on the regulation of insulin sensitivity in the adipose tissue is yet unclear. Insulin sensitivity was found to be higher in the IGF-I receptor-deficient adipocytes than that in wild-type adipocytes, suggesting that IGF-I signaling induces insulin resistance in adipocytes. However, the underlying mechanism has not yet been elucidated. In addition, the effect of superphysiological levels of IGF-I, as is observed in patients with acromegaly, on insulin sensitivity remains unclear. DESIGN: To clarify the role of IGF-I on insulin sensitivity in adipocytes, we determined insulin-induced glucose uptake and IRS-1 status in 3T3-L1 adipocytes treated with IGF-I. Since reactive oxygen species (ROS) are causally related to insulin resistance, we investigated the effect of IGF-I on ROS production to elucidate the molecular mechanism underlying insulin resistance. RESULTS: Preincubation of the adipocytes with IGF-I attenuated insulin-dependent glucose uptake. Interestingly, we found that IGF-I significantly stimulated ROS production. Furthermore, preincubation of adipocytes with an antioxidant, N-acetyl-cysteine (NAC) restored the IGF-I-induced attenuation of insulin-dependent glucose uptake; this indicates that IGF-I induces insulin resistance via ROS. Serine phosphorylation of IRS-1 was strongly induced and the insulin-dependent tyrosine phosphorylation of IRS-1 was suppressed by preincubating the adipocytes with IGF-I. Further, NAC restored these changes induced by IGF-I on both serine and tyrosine phosphorylation of IRS-1. CONCLUSIONS: These data indicate that IGF-I inhibited insulin activity in the 3T3-L1 adipocytes via ROS production, which affects IRS-1 phosphorylation status.
Subject(s)
Adipocytes/drug effects , Glucose/pharmacokinetics , Insulin-Like Growth Factor I/pharmacology , Insulin/pharmacology , Reactive Oxygen Species/metabolism , 3T3-L1 Cells , Adipocytes/metabolism , Animals , Insulin Receptor Substrate Proteins/metabolism , Insulin Resistance/physiology , Mice , NADPH Oxidases/metabolism , Oxidative Stress/physiology , Phosphorylation/drug effects , Reactive Oxygen Species/pharmacologyABSTRACT
Mechano growth factor (MGF) is an alternatively spliced variant of insulin-like growth factor-I (IGF-I). Previous reports have revealed that the MGF in skeletal muscles is induced by mechanical overload or muscle injury. In the present study, we examined the effect of growth hormone (GH) on MGF expression in C2C12 mouse muscle cell lines since GH is the principal regulator of IGF-I. The MGF mRNA increased 1 h following GH stimulation whereas IGF-IEa mRNA, which encodes a systemic type of IGF-I, increased 4 h following GH stimulation. The diverse expression of MGF and IGF-IEa was also observed in the case of muscle injury by using bupivacaine in the same cell line. Furthermore, GH induced the increase of MyoD as well as M-cadherin expression, the peak of which was parallel to that of MGF. These results indicate that GH directly and preferentially increased MGF prior to the IGF-IEa expression in C2C12 cells, which may lead to the activation of muscle satellite cells.
Subject(s)
Cell Differentiation/drug effects , Growth Hormone/pharmacology , Insulin-Like Growth Factor I/metabolism , Myoblasts/drug effects , Myoblasts/metabolism , Animals , Biomarkers , Bupivacaine/pharmacology , Cell Line , Gene Expression Regulation/drug effects , Insulin-Like Growth Factor I/genetics , Mice , MyoD Protein/metabolism , Myoblasts/cytologyABSTRACT
Mitochondrial diabetes is characterized by diabetes and hearing loss in maternal transmission with a heteroplasmic A3243G mutation in the mitochondrial gene. In patients with the mutation, it has been reported that hepatic involvement is rarely observed. We demonstrated a case of hypertrophic cardiomyopathy and hepatic failure with mitochondrial diabetes. To clarify the pathogenesis we analyzed the mitochondrial ultrastructure in the myocytes, the reactive oxygen species (ROS) production in the liver and the status of heteroplasmy of the mitochondrial A3243G mutation in the organs involved. In cardiomyocytes and skeletal muscle, electron microscopic analysis demonstrated typical morphological mitochondrial abnormalities. Immunohistochemical analysis demonstrated enhanced ROS production associated with marked steatosis in the liver, which is often associated with mitochondrial dysfunction. Analysis of the A3243G mutation revealed a substantial ratio of heteroplasmy in these organs including the liver. The presence of steatosis and enhanced oxidative stress in the liver suggested that hepatic failure was associated with mitochondrial dysfunction.
Subject(s)
Diabetes Mellitus/genetics , Genes, Mitochondrial , Liver Failure/etiology , Oxidative Stress/physiology , Autopsy , Diabetes Complications/genetics , Fatal Outcome , Genes, Mitochondrial/physiology , Humans , Liver Failure/genetics , Liver Failure/pathology , Male , Middle Aged , Mutation/physiology , Oxidative Stress/genetics , RNA, Transfer, Leu/geneticsABSTRACT
BACKGROUND/AIMS: Acromegaly is frequently accompanied with impaired glucose tolerance (IGT) and diabetes mellitus (DM). It remains unclear which factors determine the abnormal glucose tolerance status in acromegaly. In addition, diverse actions of GH and IGF-I in regulating glucose metabolism in acromegaly have not yet been well elucidated. The aim of this study was to investigate the factors associated with abnormal glucose tolerance in acromegaly. SUBJECTS AND STUDY DESIGN: We conducted a retrospective cross-sectional study that included 48 patients with active acromegaly. The subjects were divided into two groups by the results of 75 g OGTT: normal glucose tolerance (NGT) group (n = 19) and IGT+DM group (n = 29). RESULTS: Systolic blood pressure (SBP) was significantly higher in the IGT+DM than in the NGT group. Homeostasis model assessment of beta-cell function (HOMA-beta) was significantly decreased in the IGT+DM group compared with the NGT group. Although serum GH or IGF-I levels were not different between the two groups, the IGF-I/GH ratio in the IGT+DM group was significantly lower than that in the NGT group. CONCLUSIONS: We have shown that a low serum IGF-I/GH ratio was associated with abnormal glucose tolerance in acromegaly. We propose that the IGF-I/GH ratio is a useful marker to understand the metabolic status in acromegaly.
Subject(s)
Acromegaly/blood , Acromegaly/metabolism , Glucose Intolerance/blood , Growth Hormone/blood , Insulin-Like Growth Factor I/analysis , Acromegaly/complications , Acromegaly/physiopathology , Adult , Biomarkers/analysis , Biomarkers/blood , Blood Pressure , Body Mass Index , Cross-Sectional Studies , Diabetes Mellitus/etiology , Female , Glucose Intolerance/complications , Glucose Tolerance Test , Growth Hormone/analysis , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
A 16-year-old girl presented with McCune-Albright syndrome associated with acromegaly and fibrous dysplasia. Brain MRI demonstrated a pituitary tumor. X-ray films showed bone deformities, and 99TmO4 bone scintigraphy revealed increased uptake of radioactivity in the affected bones. Although the serum FGF23 level was increased, the serum calcium, phosphate, and active vitamin D levels were all within normal limits. GNAS gene mutation was detected at neither codon 201 nor 227 by conventional PCR-based direct sequencing analysis. We performed a selective PCR with peptide nucleic acid (PNA) clamping to increase the sensitivity for gene mutation detection and identified the R201C GNAS mutation.
Subject(s)
Acromegaly/genetics , Fibrous Dysplasia of Bone/genetics , Fibrous Dysplasia, Polyostotic/genetics , GTP-Binding Protein alpha Subunits, Gs/genetics , Mutation , Acromegaly/complications , Acromegaly/diagnosis , Adolescent , Chromogranins , Female , Fibroblast Growth Factor-23 , Fibrous Dysplasia of Bone/complications , Fibrous Dysplasia of Bone/diagnosis , Fibrous Dysplasia, Polyostotic/complications , Fibrous Dysplasia, Polyostotic/diagnosis , HumansABSTRACT
BACKGROUND AND AIMS: Nonalcoholic steatohepatitis (NASH) is an emerging progressive hepatic disease and demonstrates steatosis, inflammation, and fibrosis. Insulin resistance is a common feature in the development of NASH. Molecular pathogenesis of NASH consists of 2 steps: triglyceride accumulation in hepatocytes with insulin resistance and an enhanced oxidative stress caused by reactive oxygen species. Interestingly, NASH demonstrates a striking similarity to the pathologic conditions observed in adult growth hormone deficiency (AGHD). AGHD is characterized by decreased lean body mass, increased visceral adiposity, abnormal lipid profile, and insulin resistance. Moreover, liver dysfunctions with hyperlipidemia and nonalcoholic fatty liver disease (NAFLD) are frequently observed in patients with AGHD, and it is accompanied by metabolic syndrome. METHODS: We studied a case diagnosed as NASH with hyperlipidemia in AGHD. The effect of GH-replacement therapy on the patient was analyzed. RESULTS: Six months of GH-replacement therapy in the patient drastically ameliorated NASH and the abnormal lipid profile concomitant with a marked reduction in oxidative stress. CONCLUSIONS: These results suggest that GH plays an essential role in the metabolic and redox regulation in the liver.
Subject(s)
Fatty Liver/drug therapy , Hepatitis/drug therapy , Human Growth Hormone/administration & dosage , Hyperlipidemias/drug therapy , Hypopituitarism/complications , Adult , Fatty Liver/etiology , Fatty Liver/pathology , Hepatitis/etiology , Hepatitis/pathology , Human Growth Hormone/deficiency , Humans , Hyperlipidemias/etiology , Hyperlipidemias/pathology , Hypopituitarism/blood , Injections, Subcutaneous , Liver/drug effects , Liver/pathology , Male , Recombinant Proteins/administration & dosage , Severity of Illness Index , Time Factors , Treatment OutcomeABSTRACT
von Hippel-Lindau (VHL) disease (VHLD) is a hereditary autosomal dominant syndrome that causes various benign and malignant tumors. VHLD is caused by mutations in the VHL tumor suppressor gene. Here, we report a mutation in the VHL gene in a Japanese family with VHLD type 2A, characterized by pheochromocytoma (PHE), and hemangioblastomas (HAB) in both the retina and thoracic spinal cord but without renal cell carcinoma (RCC). We identified a heterozygous A to G point mutation at the second base of codon 131 of the VHL protein (pVHL). This mutation was predicted to convert codon 131 from asparagine to serine (N131S). Although most mutations in VHLD type 2A have been detected in the alpha domain of pVHL, the present mutated amino acid was located at the region encoding the beta domain of pVHL. Previous patients with the N131K or N131T mutation in pVHL developed VHLD type 2B with RCC or VHLD type 1 without PHE, respectively. We also identified somatic loss of heterozygosity (LOH) at chromosome 3p25-26 in the adrenal tumor of the patient. The results of our study suggest that not only the location of mutation but also the altered amino acid may be critical for determining the clinical phenotype of VHLD. LOH was associated with the development of PHE in a patient with the N131S mutation in pVHL.
Subject(s)
Adrenal Gland Neoplasms/genetics , Cerebellar Neoplasms/genetics , Hemangioblastoma/genetics , Mutation , Pheochromocytoma/genetics , Von Hippel-Lindau Tumor Suppressor Protein/genetics , Adrenal Gland Neoplasms/complications , Adult , Asian People , Cerebellar Neoplasms/complications , DNA Mutational Analysis , Family , Hemangioblastoma/complications , Humans , Male , Pedigree , Pheochromocytoma/complicationsABSTRACT
OBJECTIVE: Ghrelin is a potent peptide stimulating GH secretion. Besides its direct action on the pituitary, ghrelin has been reported to stimulate GH release via the vagal afferent nerve in rats. To examine the involvement of vagal nerve in ghrelin-induced GH secretion in humans, GH responses to ghrelin were compared between vagotomized patients with gastrectomy and normal subjects. METHODS: Ghrelin (0.2 microg/kg) or GHRH (1 microg/kg) was administered intravenously in vagotomized patients and normal subjects on separate days, and plasma GH responses to the stimuli were examined. RESULTS: Ghrelin caused a significant plasma GH rise in both vagotomized patients and normal subjects. Peak GH levels in vagotomized patients (37.5+/-16.9 ng/ml) were not different from those in normal subjects (29.9+/-23.1 ng/ml). The areas under the curve of GH response to ghrelin did not differ between the two groups. GHRH also increased GH levels, and peak GH levels and areas under the curve after GHRH stimulation were also comparable between vagotomized patients and normal subjects. CONCLUSIONS: In the present study, the involvement of the afferent vagal nerve in ghrelin-induced GH secretion was not confirmed in humans.